Bridge to Nowhere? Long-term outcome after prolonged ECMO therapy for COVID-19-associated ARDS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036725

Enrollment

Registered

2025-04-23

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate-to-severe ARDS

Interventions

Group 1: Prolonged ECMO (> 28 days) in patients with COVID-19 associated ARDS Group 2: Standard duration of ECMO (= 28 days) in patients with COVID-19 associated ARDS Group 3: Invasive ventilation wit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Invasive ventilation in moderate-to-severe ARDS

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
1-year mortality	—

Secondary

Measure	Time frame
moderate or severe disability (WHODAS 2.0) positive screening for posttraumatic stress disorder (IES-R) positive screening for depression (PHQ-9) degree of dependence (Modified Rankin Scale) Continuing need for oxygen supplementation Continuing need for ventilation Employment status	—

Countries

Germany

Contacts

Public ContactCarolin Jung

Medizinische Hochschule Hannover

jung.carolin@mh-hannover.de+4917615328127

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026